Connect with us

Featured Stocks

Why OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Is A Promising Stock In 2020

Published

on

OWC Pharmaceutical Research

In 2020, investors are looking for cannabis stocks that can deliver excellent returns following a disappointing 2019, which saw many pot stocks crash to multiyear lows. OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) stands out as a promising cannabis stock to own in 2020.

About OWC Pharmaceutical Research

The cannabis stock universe is vast, so for investors who may have just come across OWC Pharmaceutical for the first time an introduction of the company is in order.

OWC Pharmaceutical is an Israel-based cannabis research company. It is focused on research and development of cannabis-based medical products. The company’s work currently includes development of cannabis-based treatments for a variety of diseases and disorders such as multiple myeloma, psoriasis and fibromyalgia.

Moreover, OWC Pharmaceutical provides consulting services to both government and private entities in the field of medical cannabis programs.

OWC Pharmaceutical Research exited 2019 on a high note

While 2019 ended up being one of the toughest year for cannabis stocks, OWC Pharmaceutical had strong finish to the year. The stock gained 35% on December 31. Before that, the stock rose 65% on December 30. The back-to-back gains in the final days of 2019 helped OWC Pharmaceutical cut its losses for the year but also signaled improving investor sentiment on the stock heading into the new year.

OWC Pharmaceutical finished 2019 at $0.089, having pulled from a low of $0.0045 at the beginning of December.

What investors should note is that OWC Pharmaceutical is actually in the early stage of what is shaping up to be a powerful breakout, and so still there is a long runaway ahead.

Medical cannabis market presents huge revenue opportunity for OWC Pharmaceutical Research

OWC Pharmaceutical’s focus on development of cannabis-based treatments gives it an exposure to a huge revenue opportunity. The medical cannabis market is growing by leaps and bounds. The global medical cannabis market generated $11.8 billion in revenue in 2017, according to Zion Market Research estimates. The market is on course to grow to $40.9 billion in annual revenue by 2024.

OWC Pharmaceutical stands to benefit from the rapidly burgeoning global medical cannabis market with its clinically validated and patent protected cannabis-based treatments for some of the most troubling medical conditions.

Recent major developments at OWC Pharmaceutical Research

There have been several notable developments in recent months at OWC Pharmaceutical that could benefit the stock down the road. Here are some of those key developments:

OWC Pharmaceutical Research patent application accepted in the United States

OWC Pharmaceutical announced last month that the United States Patent and Trademark Office accepted its patent application for cannabis-based topical formulations for use skin conditions.

The cannabis extract formulation that OWC Pharmaceutical has sought patent protection for in the United States could offer relief to people suffering from skin conditions such as Psoriatic lesions of the face. Currently, this skin condition lacks an effective alternative topical remedy, which is why success in this area promises great rewards for OWC Pharmaceutical down the road.

OWC Pharmaceutical has already secured patents for its cannabis formulations for skin disorders in Australia and the Czech Republic. Now the company is on course for a significant boost to its intellectual property portfolio with a US patent for the formulations.

OWC Pharmaceutical Research partners with STENOCARE to develop cannabis medical products

In November, OWC Pharmaceutical teamed up with STENOCARE on a program to develop and commercialize cannabis-based medical products for a variety of conditions. The first product from the partnership is expected to launch in 2021 or 2022. That product will initially be sold in STENOCARE’s existing markets in Denmark and Ireland.

STENOCARE is a Danish company focused on cultivation, production, and supply of medical cannabis products for the global market. It will provide the raw materials that the partnership will work on to develop new cannabis treatments for specific conditions.

“STENOCARE is a strong match for OWC with its unique focus on pharma-grade production and distribution of medical cannabis in interesting markets. This is fully aligned with OWC’s approach to develop and commercialize products for millions of patients,” commented OWC Pharmaceutical CEO Mordechai Bignitz.

Bottom line

Considering OWC Pharmaceutical’s 2017 high just over $3, the stock has the potential to return 2600% from its current price. Therefore, taking into account OWC Pharmaceutical’s strong fundamentals as well, the stock stands out as an attractive comeback play in 2020.

We will be updating our subscribers as soon as we know more. For the latest updates on OWC Pharmaceutical Research, sign up below!

Disclosure: We have no position in OWC Pharmaceutical Research and have not been compensated for this article.

Continue Reading
1 Comment

1 Comment

  1. Howard Kalnitsky

    January 6, 2020 at 12:44 pm

    The Stenocare deal was called off…..Stenocare decided to partner with a local Danish company and not OWCP…so that point in the article is moot.

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured Stocks

Why Lexaria Bioscience Corp (OTCMKTS:LXRP) Is A Comeback Play

Published

on

Lexaria Bioscience

Lexaria Bioscience Corp (OTCMKTS:LXRP) brightest days lie ahead. The sentiments shared by Chief Executive Officer, Chris Bunka, are slowly coming to fruition, going by recent price action activity. After a steep pullback in 2019, the stock has once again started climbing higher, as investors react to milestones achieved in 2019 that affirm long-term prospects.

Lexaria Bioscience Catalysts and Price Analysis

A confirmation that the global innovator in drug delivery systems achieved almost everything it set out to accomplish in 2019 continues to strengthen market sentiments. The inking of strategic partnerships with Fortune 500 style companies is another development that the management continues to tout.

Likewise, Lexaria Bioscience succeeded in getting its DehydraTECH technology to market, consequently creating an avenue for generating long-term value. The company’s Intellectual Property strategy has also started to pay dividends, affirming what is at stake going forward. Reports that the company is already experiencing an increase in revenues is another catalyst that continues to shore the stock’s sentiments and prospects in the markets.

Lexaria Bioscience has already started bottoming out from all-time lows in what appears to be the development of a positive trend. A 10% plus rally from one-year lows continue to fuel optimism that the stock has clocked a bottom and due for a correction higher.

Standing in the way of the emerging uptrend is the $0.50 mark, which is the immediate short-term resistance level. A rally followed by a close above the…

Continue Reading

Featured Stocks

Helix TCS Stock (OTCMKTS:HLIX): A Fundamentally Attractive Investment

Published

on

Helix TCS stock

Helix TCS Stock (OTCMKTS:HLIX) is turning out to be an interesting pick after a steep pullback in 2019. The stock appears to be trading at a big discount going by the solid fundamentals that support a bounce back from current lows. If you are looking for a company seeing plenty of opportunities on the horizon then Helix TCS stock fits the bill.

Helix TCS Stock Catalysts and Price Analysis

The company is currently ranked at number 32 on the Deloitte Technology 500 fastest growing companies. The impressive rating stems from the company reporting impressive financial results depicted by an 80% increase in revenue and a 39% increase in cash flow from operations.

Likewise, the company has moved to strengthen its prospects in the hemp business by launching the nation’s first hemp tracking system. Similarly, the company has inked a strategic partnership with Alt Thirty Six for the launch of digital payments targeting thousands of dispensaries across the U.S

Reports that Helix TCS BioTrack traceability stem processed over $11 million transactions in the first week of recreational sales attest to what could turn out to be a break out year for the company and its technology.

It thus does not come as a surprise that the company’s stock has started to pick up some steam after a roller coaster 2019. A 10% plus rally since the start of the year affirms renewed investor interest in response to the wave of…

Continue Reading

Featured Stocks

Planet 13 Stock (CNSX:PLTH) (OTCMKTS:PLNHF): Is It A Buy Or Sell?

Published

on

Planet 13 stock

The marijuana stocks universe presents a variety of choices. But not all choices are great. You want to put your money in a marijuana company with a strong competitive advantage, great growth potential, and solid financials. If you are looking for a great pot stock to buy heading into 2020, Planet 13 stock (CNSX:PLTH) (OTCMKTS:PLNHF) is a strong candidate.

About Planet 13 stock

For investors who may be learning about Planet 13 Holdings for the first time, this is a vertically-integrated marijuana business. It is one of the leading marijuana companies in the Nevada market. Planet 13 Holdings is engaged in the cultivation, processing, and retail of marijuana products and it already has several marijuana brands to its credit. It operates the largest marijuana retail outlet in the world.

What you should know about Planet 13 stock

For marijuana sector in general, 2019 has generally been a rough year. Many marijuana stocks have dropped to multiyear lows. As the charts show, Planet 13 Holdings stock has been through a lot of ups and downs this year. Still, those swings have delivered decent returns for investors who know how to play stocks like Planet 13 Holdings in volatile periods.

Presently, Planet 13 Holdings stock is trading at $1.64. The stock began the year at $1.00. It jumped to $1.64 in February, thereby returning nearly 65% in space of a few weeks. There was a…

Continue Reading

MJ Stocks